Dr Thomas Seisen talks about treatment options for metastatic UTUC

Dr Thomas Seisen talks about treatment option...

Up next

EAU Section of Functional Urology: The Urologist’s Guide to suspecting neurogenic LUTS - A practical podcast for the general urologist

How can general urologists recognise when lower urinary tract symptoms may have a neurological cause, and what are the key signs that should prompt further investigation?In this episode, Prof. Sanjay Sinha is joined by Dr. Charalampos Konstantinidis, Dr. Stefania Musco and Prof. ...  Show more

EAUN edition - No place to go: Homelessness & Incontinence

This EAUN edition presents the episode “No Place to Go: Homelessness & Incontinence.” Eva Wallace, Clinical Nurse Advisor and Chair of the EAUN Special Interest Group (SIG) Continence, is joined by Anne Marie Kelly, Clinical Nurse Specialist in Continence with the Health Service ...  Show more

Recommended Episodes

Ep. 178 ASCO 2024: Game-Changing GU Oncology Updates in Bladder and Kidney Cancers with Dr. Sumanta Pal and Dr. Petros Grivas
BackTable Urology

Stay up-to-date on the latest advancements and treatment strategies in the field of genitourinary oncology. In this episode of BackTable Urology, guest host Dr. Bogdana Schmidt, a urologic oncologist from the University of Utah, discusses takeaways from ASCO 2024 with Dr. Petros ...  Show more

Ep. 267 Sequencing Therapies in NMIBC Management with Dr. Mark Tyson and Dr. Suzanne Merrill
BackTable Urology

New FDA-approved therapies for BCG-refractory non-muscle invasive bladder cancer (NMIBC)–where do they fit in the treatment algorithm, and how do you administer them? This installment of the 2025 NMIBC Creator Weekend™ series features host Dr. Bogdana Schmidt, assistant professor ...  Show more

AUA Guidelines: Treatment Of Non - Metastatic Muscle - Invasive Bladder Cancer
AUAUniversity

AUA Guidelines: Treatment Of Non - Metastatic Muscle - Invasive Bladder Cancer Guest: Jeffrey M Holzbeierlein, MD Outline: Segment #1: Guideline Statement 9-Patients who have not received cisplatin-based NAC and have pT3-4 and/or N= disease at cystectomy should receive adjuvant c ...  Show more

11: Navigating the Evolving Second-Line Landscape of Metastatic Urothelial Carcinoma
Oncology Decoded

The latest Oncology Decoded discussion with Manojkumar Bupathi, MD, MS, executive cochair of the Genitourinary Cancer Research Executive Committee at Sarah Cannon Research Institute (SCRI) and medical oncologist with Rocky Mountain Cancer Centers specializing in solid tumors and ...  Show more